Study authors | Magnocavallo et al. [17] | Elgendy et al. [18] | Şaylık et al. [19] | Yu et al. [20] | Pan et al. [21] | Zhu et al. [22] |
No. of studies included | 9 | 6 | 10 | 8 | 6 | 3 |
Year of Publication | 2022 | 2018 | 2023 | 2022 | 2021 | 2016 |
Type of studies included | RCTs | RCTs | RCTs | RCTs | RCTs | RCTs |
Total No. of patients | 2155 | 775 | 2187 | 1693 | 775 | 143 |
No. of patients in CA group | 1077 | 388 | NM | 834 | 388 | 71 |
No. of patients in MT group | 1078 | 387 | NM | 859 | 387 | 68 |
Type of ablation strategy | Pulmonary vein isolation (PVI), CFAE Ablation, Posterior Wall Isolation, SVC Isolation, Elimination of AF Triggers, Linear Ablation of the Left Atrial Roof, Cavotricuspid Isthmus and/or Mitral Isthmus | PVI | PVI | PVI, and most of the studies reported additional linear ablation and CFAE Ablation | PVI | PVI |
Type of Medical therapy | Medical rhythm and rate control drugs (Amiodarone, class IA, IC, or III) | Rate/rhythm control drugs (+Amiodarone) | Rate/rhythm control drugs | Rate/rhythm control drugs | Rate/rhythm control drugs | Rate control drugs |
Follow-up duration (months) | 12 | 26 | 12 | 12 | 16 | 12 |
Type of AF | Paroxysmal/Persistent | Paroxysmal/Persistent | Paroxysmal/Persistent | Paroxysmal/Persistent | Paroxysmal/Persistent | Persistent |
Primary outcomes | All-cause mortality and HF hospitalization | All-cause mortality | NM | All-cause mortality | All-cause mortality | ∆LVEF |
Secondary outcomes | CV death, AF recurrence rate, ∆LVEF, ∆MLHFQ, ∆VO2 max, ∆6MWT, and ∆BNP levels | HF hospitalizations, stroke, left ventricular EF improvement, Δ6MWT, ΔMLHFQ | NM | Hospitalization due to HF and the change in LVEF, 6MWT distance, peak VO2, ΔMLHFQ | Hospitalization for HF, remained in AF, change in LVEF, 6-minute walk distance, and MLHFQ. | Changes in cardiac function, exercise capacity, and QOL. |